Copay Card (Copay Coupon)

How It Works

Copay cards are manufacturer-funded discounts that reduce commercially-insured patients' cost-sharing to near-zero for brand-name drugs, typically $0-25 per fill, with annual benefit maximums of $5,000-20,000. They are available for roughly 800+ brand-name products, searchable through manufacturer websites, GoodRx, and RxAssist. The Humira Complete savings card reduced eligible patients' copays to $5/month until biosimilar pressure changed the program structure; Ozempic's savings card offers $25/month copays for commercially insured patients. Copay cards are prohibited for Medicare, Medicaid, TRICARE, VA, and other federal healthcare program beneficiaries under the Anti-Kickback Statute (42 U.S.C. 1320a-7b), with violation penalties including False Claims Act liability and exclusion from federal programs. OIG has issued multiple advisory opinions and enforcement actions, including a 2020 Regeneron settlement ($118M) over Eylea copay card misuse. Critics argue copay cards drive high drug costs by keeping patients on expensive brands instead of generic/biosimilar alternatives: the insurer still pays the negotiated high price while the patient bears no marginal cost. The Pew Charitable Trusts estimated copay cards increase commercial drug spending by roughly $30-120 billion annually. Insurers counter through copay accumulators and copay maximizers. A growing evidence base from economic studies suggests copay cards shift utilization to higher-cost brands with measurable increases in premium growth. Manufacturer industry defends copay cards as essential to patient access given high deductibles; patient advocacy organizations are split.

Related Terms

• Copay Assistance, Financial help from manufacturers, foundations, or pharmacies that reduces a patient's out-of-pocket cost for a specific drug, typically via copay cards, coupons, or charitable grants.
• Copay Accumulator, An insurance policy that does not count manufacturer copay assistance toward the patient's annual deductible or out-of-pocket maximum, shifting costs back to the patient once assistance runs out.
• Copay Maximizer, A variant of copay accumulator that calibrates the patient copay for a specialty drug to extract the maximum available manufacturer assistance, spreading it across the year.
• Patient Assistance Program (PAP), A manufacturer-sponsored program that provides free or discounted drugs to patients who meet income and insurance eligibility requirements.
• Drug Coupon Ban States, States that restrict or ban manufacturer copay coupons and drug discount cards, typically Massachusetts and California with narrower restrictions, to combat high drug costs.